TrialHaematologica2015

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Naval Daver et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.